Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
Former U.S. Senator Ben Sasse has reported a significant reduction in his pancreatic tumor size after participating in a clinical trial for an experimental drug called daraxonrasib. Initially diagnosed with stage 4 pancreatic cancer, Sasse experienced a 76% decrease in tumor volume over four months of treatment. The drug targets a key growth mechanism in cancer cells, potentially extending the lives of patients who do not respond to standard chemotherapy.
- ▪Ben Sasse was diagnosed with metastatic pancreatic cancer in December 2025.
- ▪He entered a clinical trial for daraxonrasib after being given three to four months to live.
- ▪Patients treated with daraxonrasib lived a median of 13 months compared to six months for those on chemotherapy.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fox News |
| Canonical URL | https://www.foxnews.com/health/pancreatic-cancer-patient-ben-sasse-sees-massive-tumor-reduction-experimental-drug |
| Publication time | Tue, 28 Apr 2026 07:00:47 -0400 |
| Retrieval time | 2026-04-28T11:03:38.884Z |
| Last seen | 2026-04-28T11:03:38.884Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | edq6l_9FPkPt |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Cancer News Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug Former senator calls experimental drug daraxonrasib a ‘miracle’ medication By Melissa Rudy Fox News Published April 28, 2026 7:00am EDT | Updated April 28, 2026 7:03am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Former Sen. Ben Sasse vows to fight after stage 4 pancreatic cancer diagnosis Dr. Nicole Saphier discusses former Sen. Ben Sasse’s, R-Neb., stage 4 pancreatic cancer diagnosis, new immunotherapy advances and what to know as flu season ramps up. NEWYou can now listen to Fox News articles! Months after revealing his stage 4 cancer diagnosis, former U.S. Sen.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
